Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer
Kimmie Ng, Halla Sayed Nimeiri, Nadine J. McCleary et al. · JAMA · 2019
Importance: In observational studies, higher plasma 25-hydroxyvitamin D (25[OH]D) levels have been associated with improved survival in metastatic colorectal cancer (CRC). Objective: To determine if high-dose vitamin D3 added to standard chemotherapy improves outcomes in patients with metastatic CRC. Design, Setting, and Participants: Double-blind phase 2 randomized clinical trial of 139 patients with advanced or metastatic CRC conducted at 11 US academic and community cancer centers from March 2012 through November 2016 (database lock: September 2018). Interventions: mFOLFOX6 plus bevacizumab chemotherapy every 2 weeks and either high-dose vitamin D3 (n = 69) or standard-dose vitamin D3 (n = 70) daily until disease progression, intolerable toxicity, or withdrawal of consent. Main Outcomes and Measures: The primary end point was progression-free survival (PFS) assessed by the log-rank test and a supportive Cox proportional hazards model. Testing was 1-sided. Secondary end points included tumor objective response rate (ORR), overall survival (OS), and change in plasma 25(OH)D level. Results: Among 139 patients (mean age, 56 years; 60 [43%] women) who completed or discontinued chemotherapy and vitamin D3 (median follow-up, 22.9 months), the median PFS for high-dose vitamin D3 was 13.0 months (95% CI, 10.1 to 14.7; 49 PFS events) vs 11.0 months (95% CI, 9.5 to 14.0; 62 PFS events) for standard-dose vitamin D3 (log-rank P = .07); multivariable hazard ratio for PFS or death was 0.64 (1-sided 95% CI, 0 to 0.90; P = .02). There were no significant differences between high-dose and standard-dose vitamin D3 for tumor ORR (58% vs 63%, respectively; difference, -5% [95% CI, -20% to 100%], P = .27) or OS (median, 24.3 months vs 24.3 months; log-rank P = .43). The median 25(OH)D level at baseline for high-dose vitamin D3 was 16.1 ng/mL vs 18.7 ng/mL for standard-dose vitamin D3 (difference, -2.6 ng/mL [95% CI, -6.6 to 1.4], P = .30); at first restaging, 32.0 ng/mL vs 18.7 ng/mL (difference, 12.8 ng/mL [95% CI, 9.0 to 16.6], P < .001); at second restaging, 35.2 ng/mL vs 18.5 ng/mL (difference, 16.7 ng/mL [95% CI, 10.9 to 22.5], P < .001); and at treatment discontinuation, 34.8 ng/mL vs 18.7 ng/mL (difference, 16.2 ng/mL [95% CI, 9.9 to 22.4], P < .001). The most common grade 3 and higher adverse events for chemotherapy plus high-dose vs standard-dose vitamin D3 were neutropenia (n = 24 [35%] vs n = 21 [31%], respectively) and hypertension (n = 9 [13%] vs n = 11 [16%]). Conclusions and Relevance: Among patients with metastatic CRC, addition of high-dose vitamin D3, vs standard-dose vitamin D3, to standard chemotherapy resulted in a difference in median PFS that was not statistically significant, but with a significantly improved supportive hazard ratio. These findings warrant further evaluation in a larger multicenter randomized clinical trial. Trial Registration: ClinicalTrials.gov Identifier: NCT01516216.
Cited by 184 works. doi:10.1001/jama.2019.2402 Open-access PDF
Authors
- Kimmie Ng
- Halla Sayed Nimeiri
- Nadine J. McCleary
- Thomas Adam Abrams
- Matthew B.B. Yurgelun
- James M. Cleary
- Douglas Adam Rubinson
- Deborah Schrag
- Rebecca Anne Miksad
- Andrea J. Bullock
- Jill N. Allen
- Dan Sayam Zuckerman
- Emily W. Chan
- Jennifer Ai-wen Chan
- Brian Matthew Wolpin
- Michael Constantine
- Douglas Jay Weckstein
- Meredith Gail Faggen
- Christian A. Thomas
- Chryssanthi S. Kournioti
References
- Decreased bioavailability of vitamin D in obesity
- Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988–1994,
- Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
- Extrarenal Expression of 25-Hydroxyvitamin D3-1α-Hydroxylase1
- The coming of age of 1,25-dihydroxyvitamin D3 analogs as immunomodulatory agents
- The role of vitamin D in reducing cancer risk and progression
- Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3.
- OncoTargets and Therapy
- International Journal of Cancer
- Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier